Literature DB >> 34197186

Small-Molecule Inhibition of Viral Fusion Glycoproteins.

Han-Yuan Liu1,2, Priscilla L Yang1,2.   

Abstract

Viral fusion glycoproteins catalyze membrane fusion during viral entry. Unlike most enzymes, however, they lack a conventional active site in which formation or scission of a specific covalent bond is catalyzed. Instead, they drive the membrane fusion reaction by cojoining highly regulated changes in conformation to membrane deformation. Despite the challenges in applying inhibitor design approaches to these proteins, recent advances in knowledge of the structures and mechanisms of viral fusogens have enabled the development of small-molecule inhibitors of both class I and class II viral fusion proteins. Here, we review well-validated inhibitors, including their discovery, targets, and mechanism(s) of action, while highlighting mechanistic similarities and differences. Together, these examples make a compelling case for small-molecule inhibitors as tools for probing the mechanisms of viral glycoprotein-mediated fusion and for viral glycoproteins as druggable targets.

Entities:  

Keywords:  antiviral; fusion inhibitor; inhibitor design; small molecule; viral fusion

Mesh:

Substances:

Year:  2021        PMID: 34197186      PMCID: PMC8543812          DOI: 10.1146/annurev-virology-022221-063725

Source DB:  PubMed          Journal:  Annu Rev Virol        ISSN: 2327-056X            Impact factor:   10.431


  164 in total

1.  Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

Authors:  Jean-François Bonfanti; Christophe Meyer; Frédéric Doublet; Jérôme Fortin; Philippe Muller; Laurence Queguiner; Tom Gevers; Peggy Janssens; Heidi Szel; Rudy Willebrords; Philip Timmerman; Koen Wuyts; Pieter van Remoortere; Frans Janssens; Piet Wigerinck; Koen Andries
Journal:  J Med Chem       Date:  2008-02-07       Impact factor: 7.446

2.  Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.

Authors:  Jean-François Bonfanti; Frédéric Doublet; Jérôme Fortin; Jean Lacrampe; Jérôme Guillemont; Philippe Muller; Laurence Queguiner; Eric Arnoult; Tom Gevers; Peggy Janssens; Heidi Szel; Rudy Willebrords; Philip Timmerman; Koen Wuyts; Frans Janssens; Cois Sommen; Piet Wigerinck; Koen Andries
Journal:  J Med Chem       Date:  2007-08-28       Impact factor: 7.446

3.  The role of E3 in pH protection during alphavirus assembly and exit.

Authors:  Onyinyechukwu Uchime; Whitney Fields; Margaret Kielian
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

4.  N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.

Authors:  Shibo Jiang; Hong Lu; Shuwen Liu; Qian Zhao; Yuxian He; Asim K Debnath
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.

Authors:  Zhigang Zhou; Mansoora Khaliq; Jae-Eun Suk; Chinmay Patkar; Long Li; Richard J Kuhn; Carol Beth Post
Journal:  ACS Chem Biol       Date:  2008-12-19       Impact factor: 5.100

6.  Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol.

Authors:  Irina A Leneva; Rupert J Russell; Yury S Boriskin; Alan J Hay
Journal:  Antiviral Res       Date:  2008-11-24       Impact factor: 5.970

7.  Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation.

Authors:  Stéphane Bressanelli; Karin Stiasny; Steven L Allison; Enrico A Stura; Stéphane Duquerroy; Julien Lescar; Franz X Heinz; Félix A Rey
Journal:  EMBO J       Date:  2004-02-12       Impact factor: 11.598

8.  Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.

Authors:  Qinghua Cui; Han Cheng; Rui Xiong; Gang Zhang; Ruikun Du; Manu Anantpadma; Robert A Davey; Lijun Rong
Journal:  Viruses       Date:  2018-11-30       Impact factor: 5.048

9.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

10.  How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion.

Authors:  Luke H Chao; Jaebong Jang; Adam Johnson; Anthony Nguyen; Nathanael S Gray; Priscilla L Yang; Stephen C Harrison
Journal:  Elife       Date:  2018-07-12       Impact factor: 8.713

View more
  2 in total

Review 1.  Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development.

Authors:  Henriette Ebel; Tim Benecke; Benjamin Vollmer
Journal:  Viruses       Date:  2022-08-18       Impact factor: 5.818

Review 2.  Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods.

Authors:  Geetanjali Negi; Anurag Sharma; Manorama Dey; Garvita Dhanawat; Nagma Parveen
Journal:  Biophys Rev       Date:  2022-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.